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Background/aim: This study aims to evaluate of olfactory and gustatory functions of COVID-19 patients and possible risk factors for
olfactory and gustatory dysfunctions.
Materials and methods: The cross-sectional study included adult patients who were diagnosed with COVID-19 in Gazi University
Hospital between April 2020 and June 2020. Volunteered patients participated in a survey in which olfactory and gustatory functions
and various clinical information were questioned. Sinonasal Outcome Test-22 was also administrated to all patients.
Results: A hundred and seventy-one patients participated in this study. Olfactory and gustatory dysfunctions rates were 10.5% (n:
18) and 10.5% (n: 18), respectively. Patients without any symptom other than smell and taste dysfunctions were clustered as group 1
and patients who are clinically symptomatic were clustered as group 2. Olfactory dysfunction occurred in 8% of group 1 and 17.4%
of group 2 (p = 0.072). Gustatory dysfunction rate of smokers was 19.7% and significantly higher than gustatory dysfunction rate of
nonsmokers (5.5%) (p = 0.007). Twenty-seven-point-eight percent of the patients with olfactory dysfunction (n = 5) were male and
72.2% (n: 13) were female. Sex did not show significant effect on rate of olfactory dysfunction. Twenty-five patients participated in
psychophysical olfactory function test. No participant reported olfactory dysfunction at the time of test. Of the participants, 64% (n: 16)
were normosmic and 36% (n: 9) were hyposmic according to Sniffin’ Stick test.
Conclusion: Olfactory and gustatory dysfunctions are more common in patients who are clinically symptomatic than those diagnosed
during contact tracing. Objective tests may show that frequency of olfactory dysfunction is greater than frequency of self-reported
olfactory dysfunction.
Key words: COVID-19, anosmia, ageusia, sniffin sticks

1. Introduction
Corona virus disease 2019 (COVID-19) is a pandemic that
emerged from East Asia in late 2019 and rapidly spread to
the rest of the world and caused by severe acute respiratory
syndrome Coronavirus 2 (SARS-CoV-2) [1]. The disease is
held responsible for more than 2 million deaths worldwide
and still poses a threat to the public health in most of the
countries. The most common manifestations of the disease
are fever, coughing, sore throat, and dyspnea [1,2].
Smell and taste dysfunctions have been frequently
reported since the onset of the disease. In one of the very
first reports of the neurologic manifestation of the disease,
Mao et al. reported anosmia and ageusia in 5.1% and 5.6%
of the cases, respectively [3]. Although incidences of taste
and smell dysfunctions vary among the reports, Lechien et
al. reported that 85.6% of the patients in Europe suffered

from olfactory dysfunction and 88.8% had gustatory
dysfunction [4]. Early reports claimed chemosensory
disorders may be the initial signs of the disease, especially
in the asymptomatic patients [4–7]. Sudden onset of
anosmia and ageusia within 24–48 h is reported to be
highly predictive for the disease and these symptoms often
occur within 5 days from the onset of disease [8].
Alternation of chemosensory functions due to a viral
infection is not a new phenomenon for otolaryngologists.
In adults, 40% of anosmia cases are caused by a viral
upper respiratory tract infection [9]. Common pathogens
of upper respiratory tract, rhinovirus, parainfluenza,
Epstein-Barr virus, and coronavirus are known to cause
olfactory and gustatory dysfunctions [10,11]. On the other
hand, olfactory dysfunction pathogenesis in COVID-19
seems to be on a different aspect since anosmia may occur
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without rhinorrhea or any other findings related to upper
respiratory tract infection [4,8]. Lechien et al. reported
the occurrence of anosmia or hyposmia in the absence of
rhinorrhea and nasal congestion in 79.7% of the patients
[4]. To explain mechanism of chemosensory disorders in
COVID-19 several hypotheses were raised. SARS-Cov-2
binds directly the angiotensin converting enzyme 2 (ACE
2) cell receptors. ACE2 receptors take place frequently
on olfactory epithelium and on oral cavity mucosa
particularly on the tongue but may also be detected on
glial cells and neurons of central nervous system as well
[12–14]. Epithelial damage of nasal and oral mucosa
may have a role in olfactory and gustatory dysfunctions
[15,16]. SARS-CoV-2 is shown to be neuro-invasive and
invasion of the olfactory nerve and trigeminal nerve may
cause olfactory and gustatory dysfunctions [17]. Another
hypothesis claims that central nervous system involvement
with focal encephalitis in olfactory and gustatory cortex
may be the cause of olfactory and gustatory dysfunctions.
The detection of viral RNA in cerebrospinal fluid of the
patients may support this hypothesis [3].
Even though the mechanism of olfactory and gustatory
dysfunctions in COVID-19 patients is not fully discovered,
these symptoms keep importance for suspecting of disease
and early diagnosis. In this study, we aim to evaluate
olfactory and gustatory dysfunctions of COVID-19
patients with a subjective self-reported questionnaire. We
also investigated the long-term effects of COVID-19 on
olfaction with an objective psychophysical test.
2. Material and methods
2.1. Study design
This cross-sectional study was approved by Gazi University
Ethical committee of clinical research. The study included
adult patients who diagnosed with COVID-19 in Gazi
University Hospital between April 2020 and June 2020.
The diagnosis was made with a positive SARS-Cov-2 PCR
test. The patients were invited to this study by phone. All
participants provided informed consent. In the survey,
each patient was interviewed about basic demographic
info, the time of diagnosis, hospitalization time, presence
of olfactory and gustatory dysfunctions, onset of these
symptoms (days before or days after diagnosis), recovery
of olfactory and gustatory dysfunctions, history of any
rhinologic surgery. Sinonasal Outcome Test-22 (SNOT22) was also administrated to all patients. Patients with the
history of smell or taste dysfunctions prior to COVID-19
and history of previous rhinologic surgery were excluded
from the study. Two hundred and ninety-eight patients
had been diagnosed with COVID-19 between April 2020
and June 2020. Ninety-six patients refused to participate
in the study. Five patients with olfactory dysfunction prior
to COVID-19 and 26 patients with a history of rhinologic

surgery were excluded from the study. A hundred and
seventy-one patients met the inclusion criteria.
Information on disease severity and treatment
modality was obtained from the patients’ files. The patients
were divided into groups according to disease severity.
Patients without any symptom other than smell and taste
dysfunction were clustered as group 1 and patients who
are clinically symptomatic were clustered as group 2.
Group 2 was further divided in two groups as the patients
with pneumonia were clustered as group 2b and the others
were clustered as group 2a.
2.2. Psychophysical olfactory evaluation
Patients whose recovery of the disease was shown with
two consecutive negative SARS-CoV2 tests were invited
to the clinic for objective assessment of olfaction with
Sniffin’ stick test battery (Sniffin’ Sticks, Burghart GmbH,
Wedel, Germany). Twenty-five patients volunteered
to participate. The test was performed within 45 days
and at least 30 days after the diagnosis of COVID-19.
No participant had a history of head trauma or another
episode of upper respiratory tract infection after the
diagnosis of COVID-19. The tests were performed as
previously described by Rumeau et al. [18]. All the tests
were performed in a well-ventilated, odor-free room.
The investigator who performed the test used personal
protective equipment during the procedure. An interval of
at least 8 h took place between tests to prevent spread of the
disease. Threshold (T), Discrimination (D), Identification
(I), and global scores (TDI) were recorded for each patient.
Patients with a TDI score lower than 15 are considered
anosmic, patients with a score between 15 and 30 are
considered as hyposmic, and patients with a score equal to
or higher than 30 are considered normosmic.
2.3. Statistical analysis
Statistical analysis was performed with IBM SPSS v 22.0
(IBM Corp, Armonk, New York). The Shapiro–Wilk test
was used for assessing normality. To display demographic
information, mean ± standard deviation (SD) was used
for normally distributed variables and median (min–
max) for nonnormally distributed variables. Chi-square
was used for categorical data. The Student t-test and the
Mann–Whitney U test were used to compare the normal
and nonnormally distributed data between two groups,
respectively. Spearman’s rank correlation coefficient was
used for correlation of nonnormally distributed data. The
level of statistical significance was set at p ≤ 0.05 with a
95% confidence interval.
3. Results
3.1. Demographic findings and the survey
A hundred and seventy-one patients participated in this
study. Of the participants, 58.5% (n: 100) were female and
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41.5% (n: 71) were male. The median age of the participants
was 36 (min–max: 18–71). Of the patients, 35.7% (n: 61)
were smokers and 12.9% (n: 22) were previously diagnosed
with allergic rhinitis. Participants’ demographic and clinic
information is summarized on Table 1.
The patients were clustered in three groups according
to disease severity, 73.1% of the patients (n: 125) were
in group 1 (asymptomatic other than smell or taste
dysfunction), 20.5% (n: 35) were in group 2a (symptomatic
disease without pneumonia), and 6.4% (n: 11) were in
group 2b (with pneumonia). In total, 26.9% of the patients
(n: 46) were clinically symptomatic (group 2).
Patients who suffered from olfactory dysfunction
and gustatory dysfunction comprised 10.5% (n: 18) and
10.5 (n: 18) of all the patients, respectively. Olfactory and
gustatory dysfunctions were present together in 6.4% of
the patients (n: 11). Clinical information of patients with
and without olfactory dysfunction is summarized in Table
2, and clinical information of patients with and without
gustatory dysfunction is summarized in Table 3. Olfactory
dysfunction occurred before diagnosis in 8 patients. The
median time between onset of olfactory dysfunction
and diagnosis was 2.5 days (min–max: 1–5). In 10 of the
patients, olfactory dysfunction occurred after diagnosis
with a median interval of 1 day (min–max: 1–7). All but
one patient recovered from olfactory dysfunction in a
median time of 7 days (min–max: 0–30). One patient
was still suffering from olfactory dysfunction 45 days
after diagnosis. Gustatory dysfunction occurred before
diagnosis in 8 participants within a median time of 2 days
(min–max: 1–5) and after diagnosis in 10 participants
within a median time of 1 day (min–max: 1–3). Gustatory
dysfunction resolved in 16 of the patients within a median
time of 8.5 days (min–max: 1–30).
Olfactory dysfunction occurred in 8% of group 1 and
17.4% of group 2. Olfactory dysfunction rate in group 1
was lower than that in group 2 but that was not statistically
significant (p = 0.072). Olfactory dysfunction rates in
groups 2a and 2b were 17.1% and 18.2%, respectively.
Gustatory dysfunction occurred in 8% of group 1 and in
17.4% of group 2 and that was not statistically significant
(p = 0.072). Gustatory dysfunction rates in group 2a and
2b were 17.1% and 18.2%, respectively.
The median ages of the patients who suffered from
olfactory dysfunction and who did not were 39.5 years
(min–max: 18–55) and 36 years (min–max: 19–71),
respectively (p > 0.005).
Patients with a previous diagnosis of allergic rhinitis
had a higher olfactory dysfunction rate compared to the
other patients (22.7% and 8.7%, respectively) but that
was not statistically significant (p > 0.05). Gustatory
dysfunction rates were also higher in the patients with
allergic rhinitis (22.7% vs 8.7%) (p > 0.05).
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Table 1. Demographic and clinical information of patient
participated in survey.
n

%

Male

71

41.5

Female

100

58.5

Group 1

125

73.1

Group 2a

35

20.5

Group 2b

11

6.4

Allergic rhinitis

22

12.9

Smoking

61

35.7

Olfactory dysfunction

18

10.5

Gustatory dysfunction

18

10.5

Sex

Disease Groups

Olfactory dysfunction rates in smokers and nonsmokers
were 13.1% and 9.1%, respectively. Gustatory dysfunction
rate of smokers was 19.7% and significantly higher than
gustatory dysfunction rate of nonsmokers (5.5%) (p =
0.007).
Olfactory dysfunction occurred in 7.0% of the male
patients and 13.0% of the female patients but the difference
was not significant (p = 0.16).
Mean recovery time of olfactory dysfunction was 17.3
± 12.3 days in group 2 and 9.2 ± 8.2 days in group 1. The
difference was insignificant (p > 0.05). The mean recovery
time of olfactory dysfunction of smokers was 12.6 ± 11.5
days and was similar with the mean recovery time of
nonsmokers (12.4 ± 10.3 days).
3.2. SNOT-22 questionnaire
The mean SNOT-22 score of all the patients was 11.6 ± 13.2
(min–max: 0–59). In groups 1, 2a, and 2b, the mean scores
were 10.3 ± 11.7, 17.9 ± 17.2, 6.73 ± 9.9, respectively. There
was not statistically significant difference between SNOT22 scores of groups 1 and 2 (p = 0.19).
The mean SNOT-22 score of patients who suffered from
olfactory dysfunction was 20 ± 13.4 and the mean score of
patients who did not was 10.6 ± 12.9. The difference was
statistically significant. (p = 0.001) (Table 4). The mean
SNOT 22 scores of patients who had gustatory dysfunction
and who did not were 27.2 ± 14.9 and 9.8 ± 11.8,
respectively. The difference was also statistically significant
p < 0.001). Analysis of the correlation between SNOT-22
scores and recovery times (days) of olfactory and gustatory
dysfunctions did not show significance (p > 0.05 R: 0.315).
3.3. Psychophysical olfactory evaluation
Objective olfactory evaluation with Sniffin’ sticks test
battery was performed to 25 volunteered patients, 52%
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Table 2. Comparison of patients with and without olfactory dysfunction.
With olfactory
dysfunction (18)

Without olfactory
dysfunction (153)

p

39.5 (18–55)

36 (19–71)

0.772

Male

27.8% (5)

43.1% (66)

0.159

Female

72.2% (13)

56.9% (87)

Allergic rhinitis

27.8% (5)

11.1% (17)

0.061

Smoking habit

44.4% (8)

34.6% (53)

0.411

Age median (min–max)
Sex

Table 3. Comparison of patients with and without gustatory dysfunction.
With gustatory
dysfunction (18)

Without gustatory
dysfunction (153)

p

41 (18–59)

35 (19–71)

0.199

Male

27.8% (5)

43.1% (66)

0.159

Female

72.2% (13)

56.9% (87)

Allergic rhinitis

27.8% (5)

11.1% (17)

0.061

Smoking habit

66.7% (12)

32.0% (49)

0.007

Age median (min-max)
Sex

of whom (n: 13) were female and 48% of whom (n: 12)
were male. The median age of the patients was 38 years
(min–max: 23–52). Twenty-two patients were in group 1
and three patients were in group 2a. Twenty-four percent
of the patients had a previous diagnosis of allergic rhinitis
and 48% were smokers. None of the participants had selfreported olfactory dysfunction at the time of Sniffin’ sticks
test. Only 2 patients reported olfactory dysfunction due to
COVID-19 and both claimed to be totally recovered.
The median SNOT-22 score of these 25 patients was 9
(min–max: 0–59). The median T, D, I, and TDI scores were
10.33 (min–max: 1–16), 10 (min–max: 6–16), 11 (min–
max: 8–15), and 32 (min–max: 19.33–43), respectively.
Sixty-four percent of the patients (n: 16) were normosmic
and 36% (n: 9) were hyposmic. Eleven-point-one percent
(n: 1) of the hyposmic patients had self-reported olfactory
dysfunction due to COVID-19. Eighty-one-point-three
percent of normosmic patients were in group 1. All the
hyposmic patients were in group 1. Sixty-three-pointsix percent of the hyposmic patients and 42.1% of tne
normosmic patients were smokers. Twenty-five percent of
normosmic patients and 22.2% of normosmic patients were
diagnosed with allergic rhinitis. Smoking habit and previous
diagnosis of allergic rhinitis did not differ significantly
between hyposmic and normosmic patients. Demographic
and clinical information of the patients participated in
Sniffin’ Stick Test was summarized in Table 5.

4. Discussion
Anosmia is a well-known symptom of viral upper
respiratory tract infections. A viral infection is the
reason of anosmia in 40% of the cases in adult patients
[9]. Many viruses such as rhinovirus, Epstein-Barr virus,
and parainfluenza may cause mechanical obstruction
with mucosal inflammation and rhinorrhea, resulting in
olfactory dysfunction [10,11]. However, the smell disorder
associated with COVID-19 has a different pathogenesis
that can occur without rhinorrhea and nasal obstruction
[4,8]. Lechien et al. claimed that 79.7% of COVID-19
patients with anosmia or hyposmia did not complain
about rhinorrhea and nasal obstruction [4]. On the other
hand, in our study, the mean score of “nasal obstruction”
(question-2 of SNOT-22) of the patients with self-reported
olfactory dysfunction was significantly higher than the
patients without.
In the literature, rates of olfactory dysfunction vary
among studies between 3.2% and 98.3% [19,20] and
gustatory dysfunction varies between 5.6% and 88% [3,4].
In a metaanalysis reported by Agyeman et al., olfactory
dysfunction and gustatory dysfunction rates were found
to be 41.0% (95% CI, 28.5% to 53.9%) and 38.2% (95%
CI, 24.0% to 53.6%) respectively [21]. In our study we
found that rates of olfactory and gustatory dysfunctions
were both 10.5%. We attribute our low rates of olfactory
and gustatory dysfunctions to the fact that most of the
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Table 4. SNOT-22 questionnaire and mean scores for each question.
Question

All

With olfactory
Dysfunction

Without olfactory
Dysfunction

p

1. Need to blow nose

0.36 ± 0.9

0.83 ± 1.2

0.31 ± 0.8

0.02*

2. Nasal Obstruction

0.56 ± 1

1.39 ± 1.3

0.46 ± 0.9

0.001*

3. Sneezing

0.63 ± 1

1.28 ± 1.4

0.55 ± 1

0.007*

4. Runny nose

0.46 ± 0.9

0.61 ± 1.2

0.44 ± 0.9

>0.05

5. Cough

0.61 ± 1

0.61 ± 1

0.61 ± 1

>0.05

6. Postnasal discharge

0.50 ± 1

0.83 ± 1.3

0.46 ± 0.9

>0.05

7. Thick nasal discharge

0.15 ± 0.5

0.50 ± 0.9

0.10 ± 0.4

0.005*

8. Ear fullness

0.19 ± 0.6

0.44 ± 0.9

0.16 ± 0.5

>0.05

9. Dizziness

0.31 ± 0.7

0.28 ± 0.8

0.31 ± 0.7

>0.05

10. Ear pain

0.08 ± 0.3

0.00 ± 0

0.08 ± 0.4

>0.05

11. Facial pain/pressure

0.40 ± 1

0.28 ± 1

0.42 ± 1

>0.05

12. Loss of smell or taste

0.42 ± 1.1

2.78 ± 0.9

0.14 ± 0.7

0.000*

13. Difficulty falling asleep

0.55 ± 1.1

0.94 ± 1.3

0.50 ± 1.1

>0.05

14. Waking up at night

0.63 ± 1.2

1.06 ± 1.3

0.58 ± 1.2

0.029*

15. Lack of a good night’s sleep

0.74 ± 1.3

1.17 ± 1.5

0.68 ± 1.3

>0.05

16. Waking up tired

0.88 ± 1.4

1.22 ± 1.4

0.84 ± 1.3

>0.05

17. Fatigue

0.91 ± 1.4

1.39 ± 1.5

0.85 ± 1.3

>0.05

18. Reduced productivity

0.49 ± 1

0.61 ± 1

0.47 ± 1

>0.05

19. Reduced concentration

0.48 ± 1

0.78 ± 1.3

0.44 ± 1

>0.05

20. Frustrated/restless/irritable

0.47 ± 1

0.78 ± 1.3

0.44 ± 0.9

>0.05

21. Sad

0.87 ± 1.3

1.11 ± 1.4

0.84 ± 1.3

>0.05

22. Embarrassed

0.95 ± 1.3

1.11 ± 1.4

0.93 ± 1.3

>0.05

TOTAL

11.61 ± 13.2

20.0 ± 13.4

10.62 ± 13

0.001*

Table 5. Demographic and clinical information of the patients participated in Sniffin’
stick test.
Normosmic
(n:16)

Hyposmic
(n:9)

38 (25–52)

40 (23–50)

Male

43.8%

55.6%

Female

56.3%

44.4%

Smoking

42.1%

63.6%

Allergic rhinitis

25%

22.2%

Group 1

81.3%

100%

Group 2

18.8%

–

Self-reported olfactory dysfunction

6.3%

11.1%

SNOT-22-median (min–max)

8.5 (0–59)

13 (0–22)

Age median (min–max)
Sex

Disease group
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participants in the study were asymptomatic patients
diagnosed during contact tracing.
COVID-19 may present in a wide clinical spectrum,
from asymptomatic cases to severe illness, with or without
pneumonia [22]. In our study, the patients were clustered
in three groups according to disease severity, 73.1% of the
patients were in group 1 (asymptomatic other than smell or
taste dysfunction), 20.5% were in group 2a (symptomatic
disease without pneumonia) and 6.4% were in group 2b
(presented with pneumonia). The patients in group 1
had a lower rate of olfactory dysfunction compared to
group 2 but that was not statistically significant. Several
authors reported lower olfactory disorder rates in severe
COVID-19 [23–26]. However, in the studies that used
psychophysical olfactory tests, no relationship between
disease severity and olfactory dysfunction was found
[8,20,26,27].
Some studies reported significantly higher olfactory
dysfunction rates in females than in males [4,28,29]. In
our study, the rate of self-reported olfactory dysfunction
was higher in females (13% vs. 7%) but that was not
statistically significant. The relation between smoking and
self-reported olfactory dysfunction varies among studies
[24,30]. In our study, the rate of olfactory dysfunction of
smokers was similar to that of nonsmokers. The mean ages
of the patients with and without self-reported olfactory
dysfunction were 39.5 (min–max: 18–55) and 36 (min–
max: 19–71) respectively. Vaira et al. evaluated a large
group of patients with psychophysical olfactory tests and
did not find a relationship between age, sex, smoking, and
olfactory dysfunction [31].
In our study, gustatory dysfunction rate of smokers
was significantly higher than that of nonsmokers. No
information was found in the literature on how smoking
affects the susceptibility to gustatory dysfunction in
COVID-19 patients. On the other hand, smoking is known
to cause alternations of gustatory function [32].
All but one patient recovered from olfactory
dysfunction in median time of 7 days (min–max: 0–30).
One patient was still suffering from olfactory dysfunction
45 days after diagnosis. Gustatory dysfunction resolved in
16 of the patients within a median time of 8.5 days (min–
max: 1–30). These findings were in line with the literature.
In the study by Lechien et al. 96.7% of the patients recovered
in two weeks [4]. Klepfenstein et al. pointed out that the
average duration of anosmia was 8.9 days and ≥14 days for
20% of individuals [33]. Lee et al. reported that patients
with olfactory or gustatory dysfunctions recovered within
3 weeks; with the average recovery time of 7 days [29].
SNOT-22 score of group 2a was higher than the others.
Lechien et al. also reported higher SNOT-22 scores in the
patients with moderate disease than patients with mild or
severe disease [34]. Since the first 12 questions of SNOT-

22 mostly cover the symptoms of upper respiratory tract
infection, it was not surprising to have higher SNOT22 scores in patients with moderate symptoms without
pulmonary disease. Samaranayake et al. pointed out that
“nasal blockage” (question 2) and “runny nose” (question
4) were more prevalent in patients with mild or moderate
disease than patients with severe disease [35].
In the second step of our study, we aimed to evaluate
olfactory function of recovered patients with sniffin’ sticks
test battery. All the tests were performed at least 30 days
after the diagnosis. No participant reported olfactory
dysfunction at the time of test. According to TDI scores,
64% of the patients were normosmic and 36% were
hyposmic. Moein et al. reported that nearly 65% of the
patients were unaware of their olfactory dysfunction [20].
Vaira et al. reported that 14.5% of the patients without selfreported olfactory dysfunction were actually hyposmic
[31]. On the other hand, being unaware of olfactory
dysfunction is not rare with a prevalence of %22 in normal
population [36]. According to this information, it may
be wrong to say that hyposmia in our patients is caused
by COVID-19, but it could be speculated that olfactory
dysfunction is more common in COVID patients than
patients’ self-report.
There was not any significant difference of age, sex,
severity of disease, and diagnosis of allergic rhinitis
between normosmic and hyposmic patients. The median
SNOT-22 score was higher in hyposmic patients.
This study has several limitations. Firstly, both the
survey and psychophysical olfactory tests were performed
after the patients’ recovery. The survey was based on
patients’ self-reported data. This posed a risk for recall
bias. Secondly, almost all the patients who participated
in psychophysical olfactory tests were those who did
not report olfactory dysfunction during COVID-19.
Therefore, no comment could be made on the permanence
of the olfactory dysfunction caused by COVID-19. A third
limitation was that the olfactory functions of the patients
who underwent psychophysical olfactory tests were not
objectively known prior to disease. Therefore, it could not
be clarified whether the hyposmia in our patients was due
to COVID or not.
5. Conclusion
Olfactory and gustatory dysfunctions have been a
remarkable issue for physicians since the beginning of the
COVID-19 outbreak. These symptoms occur in the early
period of the disease. Olfactory and gustatory dysfunctions
are more common in patients who are clinically
symptomatic than those diagnosed during contact tracing.
Olfactory dysfunction is not related to the severity of
the disease. Objective tests may show that frequency of
olfactory dysfunction is greater than frequency of selfreported olfactory dysfunction.
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